Clinical Trial Update: A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors [Phase 1]

View source ↗

Summary

This Phase I study assesses the safety, pharmacokinetics, and pharmacodynamics of GSK2118436 (dabrafenib) in patients with solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• GSK2118436 (dabrafenib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 1 | Status: COMPLETED